Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: A comprehensive review

被引：47

作者：

Assi, Tarek ^{[1
]}

Kattan, Joseph ^{[1
]}

Rassy, Elie ^{[1
,2
]}

Nassereddine, Hussein ^{[1
]}

Farhat, Fadi ^{[1
]}

Honore, Charles ^{[2
]}

Le Cesne, Axel ^{[2
]}

Adam, Julien ^{[2
]}

Mir, Olivier ^{[2
]}

机构：

[1] St Joseph Univ, Dept Hematol Oncol, Fac Med, Beirut, Lebanon

[2] French Sarcoma Grp, Gustave Roussy Canc Campus, Villejuif, France

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2020年 / 153卷

关键词：

Liposarcoma; Soft tissue sarcoma; CDK4; MDM2; Palbociclib; Abemaciclib; Ribociclib; SOFT-TISSUE SARCOMA; PHASE-II; 1ST-LINE TREATMENT; SYNOVIAL SARCOMA; INHIBITOR; CANCER; DOXORUBICIN; ABEMACICLIB; PALBOCICLIB; EFFICACY;

D O I：

10.1016/j.critrevonc.2020.103029

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Well-differentiated/dedifferentiated (WD/DD) liposarcomas, the most common form of liposarcomas, constitute up to 20 % of all soft tissue sarcomas. Several oncogenes are thought to be involved in liposarcoma pathogenesis, mainly MDM2, CDK4 and HMGA2. While MDM2 inhibitors are now tested in clinical trials, a second actionable and promising target appears to be cyclin-dependent kinase 4 (CDK4), which is amplified in up to 90 % of well differentiated or dedifferentiated (WD/DD) liposarcoma. With the paucity of available therapeutic options, the inhibition of CDK4 represent a potential therapeutic option. In this paper, we review the role of CDK4/6 inhibitors in targeting the commonly identified CDK4 amplification in WD/DD liposarcoma, with an emphasis on the published and currently ongoing trials.

引用

页数：6

共 50 条

[41] Flavopiridol induces G(1) arrest with inhibition of cyclin-dependent kinase (CDK)2 and CDK4 in human breast carcinoma cells
Carlson, BA
Dubay, MM
Sausville, EA
Brizuela, L
Worland, PJ
CANCER RESEARCH, 1996, 56 (13) : 2973 - 2978
[42] Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor
Liu, Ning-Ai
Jiang, Hong
Ben-Shlomo, Anat
Wawrowsky, Kolja
Fan, Xue-Mo
Lin, Shuo
Melmed, Shlomo
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (20) : 8414 - 8419
[43] A comprehensive bioinformatic analysis of cyclin-dependent kinase 2 (CDK2) in glioma
Liu, Hengrui
Weng, Jieling
GENE, 2022, 822
[44] Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i): Mechanisms of resistance and where to find them
Foffano, L.
Cucciniello, L.
Nicolo, E.
Migliaccio, I.
Noto, C.
Reduzzi, C.
Malorni, L.
Cristofanilli, M.
Gerratana, L.
Puglisi, F.
Pitigliani, Sandro
BREAST, 2025, 79
[45] Basic Pan-Cancer Analysis of the Carcinogenic Effects of Cyclin-Dependent Kinase 4 (CDK4) in Human Surface Tumors
Wu, Jingping
Deng, Tinghan
Huang, Yuanen
Cheng, Hongbin
JOURNAL OF HEALTHCARE ENGINEERING, 2021, 2021
[46] Targets of the cyclin-dependent kinase Cdk1
Jeffrey A. Ubersax
Erika L. Woodbury
Phuong N. Quang
Maria Paraz
Justin D. Blethrow
Kavita Shah
Kevan M. Shokat
David O. Morgan
Nature, 2003, 425 : 859 - 864
[47] Targets of the cyclin-dependent kinase Cdk1
Ubersax, JA
Woodbury, EL
Quang, PN
Paraz, M
Blethrow, JD
Shah, K
Shokat, KM
Morgan, DO
NATURE, 2003, 425 (6960) : 859 - 864
[48] Review of rationale and progress toward targeting cyclin-dependent kinase 2 (CDK2) for male contraception
Faber, Erik B.
Wang, Nan
Georg, Gunda, I
BIOLOGY OF REPRODUCTION, 2020, 103 (02) : 357 - 367
[49] Cyclin-dependent kinase (CDK) inhibitors in solid tumors: a review of clinical trials
Panagiotou, E.
Gomatou, G.
Trontzas, I. P.
Syrigos, N.
Kotteas, E.
CLINICAL & TRANSLATIONAL ONCOLOGY, 2022, 24 (02): : 161 - 192
[50] Cyclin-dependent kinase (CDK) inhibitors in solid tumors: a review of clinical trials
E. Panagiotou
G. Gomatou
I. P. Trontzas
N. Syrigos
E. Kotteas
Clinical and Translational Oncology, 2022, 24 : 161 - 192

← 1 2 3 4 5 →